Ozempic Lawsuit Filed Over Gastroparesis and Necrotizing Pancreatitis Injuries
Necrotizing pancreatitis is caused by the death of pancreas tissue, resulting in infections and lower pancreas functionality which can limit digestion.
Necrotizing pancreatitis is caused by the death of pancreas tissue, resulting in infections and lower pancreas functionality which can limit digestion.
Findings align with warnings issued by anesthesiologists last summer about Ozempic aspiration risks, following reports of life-threatening problems caused by delayed gastric emptying during surgery.
Lawyers indicate that that questions about whether the GLP-1 RA medication label warnings adequately disclose the risk of gastroparesis and other severe injuries will play a large role in the growing litigation.
Death reports linked to Ozempic and similar drugs indicate users suffered from intestinal masses, stomach paralysis, pancreatic cancer and seizures.
Lawsuit indicates that Novo Nordisk fails to adequately disclose serious risks, indicating some doctors estimate 10% of users discontinue due the severity of the Ozempic side effects.
The U.S. District Judge recently appointed to preside over all federal GLP-1 RA lawsuits is expected to appoint a group of Ozempic lawyers to take certain actions during the MDL proceedings that benefit all plaintiffs.
FDA approved expanded use of Wegovy for cardiovascular disease caused by being overweight, as concerns continue to grow about reports of stomach paralysis injuries some users are experiencing.
Drug maker plans to pursue legal remedies against compounding pharmacies, medical spas and other entities that claim to sell generic versions of Mounjaro and Zepbound.
New York woman indicates she had to undergo an emergency resection of her bowels and now needs to use a colostomy bag as a result of gastroparesis and intestinal obstructions from Mounjaro
Lawyers involved in stomach paralysis lawsuits against Ozempic, Wegovy and other GLP-1 medication manufacturers will meet with the judge to discuss the organizational structure of the recently formed MDL.